Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DepoCyte (Pacira BioSciences, 844e67)
- Development stage
- Unknown
- Lead developer
- SkyePharma
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intrathecal
01
Overview
DepoCyte is a sustained-release liposomal formulation of the antimetabolite cytarabine (Ara-C), specifically engineered for intrathecal administration into the cerebrospinal fluid. Utilizing the proprietary DepoFoam multivesicular liposome technology, it provides a slow release of cytarabine, maintaining cytotoxic concentrations in the neuroaxis for up to 14 days, which significantly reduces the frequency of injections compared to standard cytarabine. The active ingredient, cytarabine, is a pyrimidine analog that, upon intracellular phosphorylation, inhibits DNA polymerase and incorporates into DNA, leading to S-phase specific cell death. While it received regulatory approval for the treatment of lymphomatous meningitis, it has been investigated in clinical trials such as the GMALL Elderly 1/2003 study led by Goethe University for central nervous system prophylaxis and treatment in elderly patients with acute lymphoblastic leukemia (ALL). However, the product was discontinued globally in 2017 due to persistent technical manufacturing complexities.
- Brand names
- DepoCyte
- Other names
- liposomal cytarabinecytarabine liposome injectionAra-C liposomal
02
Targets
DNA polymerase familyDNA
Beyond the preview
Go deeper on DepoCyte (Pacira BioSciences, 844e67).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DepoCyte (Pacira BioSciences, 844e67).